Journal
CLINICAL & TRANSLATIONAL ONCOLOGY
Volume 25, Issue 3, Pages 830-840Publisher
SPRINGER INT PUBL AG
DOI: 10.1007/s12094-022-02994-6
Keywords
P53; CDK9; Bladder cancer; Expression; Prognosis
Categories
Ask authors/readers for more resources
This study found that high expression of p53 is associated with unfavorable clinical features in bladder cancer and is correlated with the expression of CDK9. CDK9 may influence p53 expression through interactions with p53 inhibitors. Confirming the crosstalk between p53 and CDK9 in bladder cancer may be an important step in explaining the mechanism of tumor progression in its early stages.
Purpose The mutation of p53 is considered a pivotal step in bladder cancer pathogenesis. Recently, distinct interactions between p53 and CDK9, a transcription regulator, have been described. In this work, we explored the prognostic role of p53 expression and evaluated its associations with CDK9 in urothelial carcinoma. Materials and methods The research group consisted of 67 bladder cancer samples and 32 normal urothelial mucosa samples. All specimens were analyzed using ImageJ and the IHC profiler plugin. To validate the results, 406 cases from The Cancer Genome Atlas database were analyzed. Results P53 and CDK9 are overexpressed in urothelial cancer tissues when compared to normal urothelial tissues (p < 0.05). High p53 expression was observed in metastatic tumors and tumors with high CDK9 expression (p < 0,05). High p53 expression was predictive for shorter survival in patients with non-muscle-invasive bladder cancer (HR = 0.107 [0.012-0.96]; p = 0.046) but did not correlate with prognosis in the muscle-invasive group. In high CDK9 cancers, high p53 expression correlated with the occurrence of high-grade and muscle-invasive tumors (p < 0.05). Conclusion High expression of p53 correlates with unfavorable clinical features of bladder cancer. CDK9 is associated with the expression of p53, possibly through interactions with p53 inhibitors. Since the blockade of CDK9 in other malignancies reactivates wild-p53 activity, confirming the crosstalk between p53 and CDK9 in bladder cancer may be another step to explain the mechanism of tumor progression in its early stages.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available